News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Citigroup has maintained its "Buy" rating on Veradermics. The article indicates a positive outlook from the analytical firm regarding the company.
Veradermics (NYSE:MANE) shares gapped up significantly after Needham & Company raised its price target and reaffirmed a buy rating. This positive movement was further fueled by encouraging Phase 2 data for the company's oral hair-loss drug, VDPHL01, showing improved outcomes for women with pattern …
Veradermics' experimental baldness drug, VDPHL01, an extended-release minoxidil, showed promising Phase 2 results in women with mild-to-moderate pattern hair loss, exceeding investor expectations. The drug led to a mean increase of about 23 hairs per square centimeter after six months, with most participants and …
Veradermics announced positive topline results from its Phase 2 clinical trial (Study ‘207’) for VDPHL01, an oral minoxidil formulation for female pattern hair loss. The treatment showed fast onset of hair growth, with a high percentage of patients reporting improvement by Month 6. Veradermics …
Veradermics Incorporated (MANE) stock has seen a significant 12.28% increase due to positive dermatology trial results, attracting active traders. Despite recent pullbacks from highs near $130, the company boasts a strong cash position of $168 million with minimal liabilities, providing a substantial runway for …
Shares of Veradermics (MANE) rose significantly after the company released positive topline data from a Phase 2 study for its lead asset, VDPHL01. This data pertains to the treatment of female pattern hair loss and validates the design of an upcoming registrational trial. The …
Veradermics, Inc. reported positive Phase 2 data for VDPHL01, an extended-release oral minoxidil tablet, in women with mild-to-moderate pattern hair loss. The study showed significant hair growth and high patient-reported improvement with good tolerability, positioning VDPHL01 as a potential first FDA-approved oral treatment for …
Veradermics has announced positive Phase 2 results for VDPHL01, an oral non-hormonal hair loss drug for women. The study showed significant improvement in hair growth at 24 weeks, supporting its advancement to Phase 3. If approved, VDPHL01 would be the first FDA-approved oral non-hormonal …
Veradermics has announced positive topline results from a Phase 2 study of its oral minoxidil formulation, VDPHL01, for female pattern hair loss. The drug demonstrated a "potentially differentiated clinical profile" with swift onset, consistent patient responses, and significant hair count increases. Analysts are optimistic …
Veradermics announced positive Phase 2 clinical trial results for its oral VDPHL01, an extended-release minoxidil formulation, in female pattern hair loss. The study showed rapid onset of hair growth, with up to 90% of participants reporting improved hair coverage by Month 6, and a …
Veradermics shares rose 9% following positive Phase 2 clinical trial results for VDPHL01, an oral treatment for female pattern hair loss. The study showed significant improvement in hair count and a favorable safety profile. The company anticipates further trial results later in 2026 and …
B.Riley has initiated coverage on Veradermics Inc. (NYSE:MANE) with a Buy rating and a price target of $170.00, driven by excitement over the company's lead hair loss drug candidate, VDPHL01. This drug is an extended-release oral minoxidil aiming to be the first FDA-approved oral …
Search by ticker symbol or company name and select a result to open its chart.